Annual Total Long Term Liabilities
$65.96 M
-$62.38 M-48.61%
31 December 2023
Summary:
Supernus Pharmaceuticals annual total long term liabilities is currently $65.96 million, with the most recent change of -$62.38 million (-48.61%) on 31 December 2023. During the last 3 years, it has fallen by -$448.18 million (-87.17%). SUPN annual total long term liabilities is now -88.18% below its all-time high of $557.92 million, reached on 31 December 2021.SUPN Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$44.04 M
-$5.68 M-11.42%
30 September 2024
Summary:
Supernus Pharmaceuticals quarterly total long term liabilities is currently $44.04 million, with the most recent change of -$5.68 million (-11.42%) on 30 September 2024. Over the past year, it has dropped by -$41.39 million (-48.45%). SUPN quarterly long term liabilities is now -92.11% below its all-time high of $557.92 million, reached on 31 December 2021.SUPN Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -48.6% | -48.5% |
| 3 y3 years | -87.2% | -91.4% |
| 5 y5 years | -81.8% | -89.0% |
SUPN Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -88.2% | at low | -92.1% | at low |
| 5 y | 5 years | -88.2% | at low | -92.1% | at low |
| alltime | all time | -88.2% | +390.9% | -92.1% | +308.5% |
Supernus Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $44.04 M(-11.4%) |
| June 2024 | - | $49.72 M(-17.6%) |
| Mar 2024 | - | $60.37 M(-8.5%) |
| Dec 2023 | $65.96 M(-48.6%) | $65.96 M(-22.8%) |
| Sept 2023 | - | $85.44 M(-29.2%) |
| June 2023 | - | $120.60 M(-18.6%) |
| Mar 2023 | - | $148.11 M(+15.4%) |
| Dec 2022 | $128.35 M(-77.0%) | $128.35 M(+12.2%) |
| Sept 2022 | - | $114.34 M(-3.1%) |
| June 2022 | - | $118.00 M(-77.6%) |
| Mar 2022 | - | $526.51 M(-5.6%) |
| Dec 2021 | $557.92 M(+8.5%) | $557.92 M(+9.4%) |
| Sept 2021 | - | $509.86 M(+1.2%) |
| June 2021 | - | $504.03 M(-1.6%) |
| Mar 2021 | - | $512.19 M(-0.4%) |
| Dec 2020 | $514.14 M(+27.2%) | $514.14 M(+2.5%) |
| Sept 2020 | - | $501.54 M(-9.8%) |
| June 2020 | - | $555.77 M(+36.2%) |
| Mar 2020 | - | $408.15 M(+1.0%) |
| Dec 2019 | $404.27 M(+11.2%) | $404.27 M(+1.1%) |
| Sept 2019 | - | $399.94 M(+0.8%) |
| June 2019 | - | $396.80 M(+0.8%) |
| Mar 2019 | - | $393.72 M(+8.3%) |
| Dec 2018 | $363.44 M(+969.4%) | $363.44 M(+0.3%) |
| Sept 2018 | - | $362.23 M(+1.1%) |
| June 2018 | - | $358.37 M(+1.2%) |
| Mar 2018 | - | $354.20 M(+942.3%) |
| Dec 2017 | $33.98 M | $33.98 M(+17.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2017 | - | $28.86 M(-8.2%) |
| June 2017 | - | $31.45 M(-8.0%) |
| Mar 2017 | - | $34.19 M(-7.8%) |
| Dec 2016 | $37.07 M(-15.1%) | $37.07 M(-7.5%) |
| Sept 2016 | - | $40.10 M(+233.1%) |
| June 2016 | - | $12.04 M(-1.4%) |
| Mar 2016 | - | $12.21 M(-72.0%) |
| Dec 2015 | $43.69 M(-35.7%) | $43.69 M(+207.5%) |
| Sept 2015 | - | $14.21 M(-7.7%) |
| June 2015 | - | $15.39 M(-15.4%) |
| Mar 2015 | - | $18.20 M(-73.2%) |
| Dec 2014 | $67.96 M(+32.9%) | $67.96 M(+78.5%) |
| Sept 2014 | - | $38.08 M(-8.5%) |
| June 2014 | - | $41.63 M(+0.6%) |
| Mar 2014 | - | $41.41 M(-19.0%) |
| Dec 2013 | $51.13 M(+280.6%) | $51.13 M(-40.7%) |
| Sept 2013 | - | $86.24 M(+7.7%) |
| June 2013 | - | $80.06 M(+642.6%) |
| Mar 2013 | - | $10.78 M(-19.8%) |
| Dec 2012 | $13.44 M(-47.3%) | $13.44 M(-24.5%) |
| Sept 2012 | - | $17.79 M(-11.5%) |
| June 2012 | - | $20.10 M(-12.7%) |
| Mar 2012 | - | $23.02 M(-9.8%) |
| Dec 2011 | $25.52 M(-66.5%) | $25.52 M(-71.1%) |
| Sept 2011 | - | $88.32 M(+16.0%) |
| Dec 2010 | $76.12 M(+0.1%) | $76.12 M(+0.1%) |
| Sept 2010 | - | $76.01 M(-0.0%) |
| Dec 2009 | $76.02 M(+0.5%) | $76.02 M |
| Dec 2008 | $75.61 M | - |
FAQ
- What is Supernus Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual total long term liabilities year-on-year change?
- What is Supernus Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly long term liabilities year-on-year change?
What is Supernus Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of SUPN is $65.96 M
What is the all time high annual total long term liabilities for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual total long term liabilities is $557.92 M
What is Supernus Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, SUPN annual total long term liabilities has changed by -$62.38 M (-48.61%)
What is Supernus Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of SUPN is $44.04 M
What is the all time high quarterly long term liabilities for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly total long term liabilities is $557.92 M
What is Supernus Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, SUPN quarterly total long term liabilities has changed by -$41.39 M (-48.45%)